Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Renal Cell Carcinoma, Metastatic Kidney Cancer
Interventions: Pembrolizumab Injection [Keytruda], Cryoablation, Nephrectomy; Drug · Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orange, California

Conditions: Stroke
Interventions: Hybrid combination of physical therapy and powered exoskeleton, Powered Exoskeleton Only, Physical Therapy only; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Lung Cancer
Interventions: Questionnaires, Meditation and Discussion Sessions, Cancer-Related Discussion Program; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions: CC-122; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Infection
Interventions: omiganan 1% gel, chlorhexidine 2% solution; Drug
Lead sponsor: Cadence Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Diabetes Mellitus, Type 2
Interventions: GLWL-01, Part A, Placebo, Part A, GLWL-01, Part B, Placebo, Part B, GLWL-01, Part C, Placebo, Part C; Drug
Lead sponsor: GLWL Research Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Tempe, Arizona • Chula Vista, California • Miami, Florida + 1 more

Conditions: Caregivers, Family Relations, Domestic Violence, Elder Abuse
Interventions: KINDER; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Transplant Recipients, Old Age
Interventions: Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: ACP-196, Calcium carbonate, Omeprazole, Rifampin; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Granulomatous Disease, Chronic, X-linked
Interventions: Lentiviral G1XCGD Gene Therapy; Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 23 Months and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts

Conditions: Glioblastoma, Gliosarcoma
Interventions: Temozolomide, Radiation, Sorafenib; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Small Cell Lung Cancer
Interventions: Cisplatin, Etoposide, Placebo, ZD6474; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 19
States / cities: Newark, Delaware • Chicago, Illinois • Galesburg, Illinois + 13 more

Conditions: Diet, Healthy Growth
Interventions: Family support, BGCAA's after-school program with CATCH curriculum; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 5 Years to 11 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza Vaccination
Interventions: Opting Out; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Galveston, Texas • Houston, Texas

Conditions: Healthy Volunteers
Interventions: TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Nasopharyngeal Carcinoma
Interventions: Toripalimab, Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer, Ovarian Neoplasm, Pain
Interventions: Omega-3 fatty acid, Placebo, Paclitaxel; Dietary Supplement · Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Hypercapnia, Ventilatory Depression
Interventions: Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
Interventions: EZM0414; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more

Conditions: Advanced Solid Tumors
Interventions: Paclitaxel, RO5509554; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Post Traumatic Stress Disorder
Interventions: Methylone; Drug
Lead sponsor: Transcend Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Lauderhill, Florida • Maitland, Florida • Orlando, Florida + 5 more

Conditions: Healthy Volunteer
Interventions: CC-122, Itraconazole, Fluvoxamine, Rifampin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ankle Fractures
Interventions: Ankle Muscle Power (AMP) program, Standard of Care; Other · Behavioral
Lead sponsor: Brian W. Noehren; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Immunoglobulin A (IgA) Nephropathy
Interventions: PS-002; Genetic
Lead sponsor: Purespring Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Miami, Florida • Baltimore, Maryland

Search by objective public record fields.

Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

A Comparison of Conventional Physical Therapy, Powered Exoskeleton, and Hybrid Physical Therapy With Exoskeleton

Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Knowledge and Interpersonal Skills to Develop Exemplary Relationships

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

'Food, Fun, Fresh, Family' Program for Healthy Eating and Growth for Elementary-age Children.

Opting In vs Opting Out

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Efficacy and Clinical Feasibility of the Ankle Muscle Power (AMP) Program for Return to Duty After an Ankle Fracture

PS-002 for the Treatment of IgA Nephropathy in Adults